Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia

Pediatric Blood and Cancer

Volumn 56, Issue 3, 2011, Pages 420-424

  Chang, Hsiu Hao ^a,b   Lu, Meng Yao ^a   Liao, Yu Mei ^c   Lin, Pei Chin ^c   Yang, Yung Li ^a,b   Lin, Dong Tsamn ^a   Chiou, Shyh Shin ^c,d   Jou, Shiann Tarng ^a   Lin, Kai Hsin ^a   Chang, Tai Tsung ^c,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Deferasirox; Iron overload; Thalassemia; Twice daily dosing

Indexed keywords

DEFERASIROX; FERRITIN;

ADULT; ARTHRALGIA; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL PAIN; HUMAN; IRON OVERLOAD; MALE; MEDICAL RECORD REVIEW; PANCREATITIS; PRIORITY JOURNAL; SIDE EFFECT; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MAXIMUM TOLERATED DOSE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 78651061167     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22826     Document Type: Article

References (11)

1. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 2006; 107: 3436-3441.
2. Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009; 122: 165-173.
3. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91: 1343-1351.
4. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
5. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per day in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752-759.
6. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009; 114: 4009-4013.
7. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880.
8. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-566.
9. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565-572.
10. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
11. Otto-Duessel M, Aguilar M, Nick H, et al. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol 2007; 35: 1069-1073.